RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+4.99%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.3B
AUM Growth
+$273M
Cap. Flow
+$275M
Cap. Flow %
11.97%
Top 10 Hldgs %
43.45%
Holding
85
New
20
Increased
27
Reduced
19
Closed
15
Avg Time Held
1 year
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$73.7M
2
ABT icon
Abbott
ABT
+$49.7M
3
BLUE icon
bluebird bio
BLUE
+$40.7M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$37.3M
5
TFX icon
Teleflex
TFX
+$35.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.2M
2
AET
Aetna Inc
AET
+$37.2M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$34.4M
4
MOH icon
Molina Healthcare
MOH
+$31.7M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.29%
2 Financials 1.18%
3 Miscellaneous 0.94%
4 Communication Services 0.58%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CTMX icon
51
CytomX Therapeutics
CTMX
$486M
$8.84M 0.38%
418,680
+36,409
+10% +$755K
2015 Q4
8 quarters
GMED icon
52
Globus Medical
GMED
$10.2B
$8.57M 0.37%
+208,600
New +$7.3M
2017 Q4
0 quarters
ATYR icon
53
aTyr Pharma
ATYR
$18M
$6.6M 0.29%
134,771
– –
2017 Q3
1 quarter
SYRS icon
54
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.2M 0.27%
63,723
-419
-0.7% -$56.3K
2016 Q2
6 quarters
TDOC icon
55
Teladoc Health
TDOC
$1.04B
$5.23M 0.23%
+150,000
New +$4.98M
2017 Q4
0 quarters
PRQR icon
56
ProQR Therapeutics
PRQR
$209M
$5.03M 0.22%
1,558,392
-44,583
-3% -$160K
2014 Q3
13 quarters
PETQ icon
57
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$4.9M 0.21%
224,343
-22,400
-9% -$516K
2017 Q3
1 quarter
OVID icon
58
Ovid Therapeutics
OVID
$428M
$3.09M 0.13%
312,782
-138,400
-31% -$1.27M
2017 Q2
2 quarters
ACRS icon
59
Aclaris Therapeutics
ACRS
$498M
$2.64M 0.11%
107,020
+6,060
+6% +$148K
2016 Q4
4 quarters
CASC
60
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.4M 0.1%
649,446
-1,320,523
-67% -$5.41M
2017 Q1
3 quarters
NKTR icon
61
Nektar Therapeutics
NKTR
$1.26B
$318K 0.01%
355
-617
-63% -$365K
2017 Q2
2 quarters
HZNP
62
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$292K 0.01%
+20,000
New +$281K
2017 Q4
0 quarters
ALGN icon
63
Align Technology
ALGN
$10.2B
$253K 0.01%
+1,140
New +$259K
2017 Q4
0 quarters
HUM icon
64
Humana
HUM
$51.6B
$248K 0.01%
+1,000
New +$247K
2017 Q4
0 quarters
PCRX icon
65
Pacira BioSciences
PCRX
$1.45B
$237K 0.01%
+5,190
New +$206K
2017 Q4
0 quarters
BMRN icon
66
BioMarin Pharmaceuticals
BMRN
$10.7B
$223K 0.01%
+2,500
New +$217K
2017 Q4
0 quarters
VCRA
67
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$212K 0.01%
+7,000
New +$200K
2017 Q4
0 quarters
ADVM icon
68
DELISTED
Adverum Biotechnologies
ADVM
$78K ﹤0.01%
2,224
– –
2016 Q2
6 quarters
CSLT
69
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$38K ﹤0.01%
10,229
– –
2016 Q2
6 quarters
AMED icon
70
DELISTED
Amedisys
AMED
– –
-283,648
Closed -$15.9M –
AUPH icon
71
Aurinia Pharmaceuticals
AUPH
$2.21B
– –
-332,310
Closed -$2.08M –
BSX icon
72
Boston Scientific
BSX
$62.4B
– –
-603,493
Closed -$17.6M –
HOLX icon
73
DELISTED
Hologic
HOLX
– –
-20,000
Closed -$734K –
MEDP icon
74
Medpace
MEDP
$17.3B
– –
-499,640
Closed -$15.9M –
MOH icon
75
Molina Healthcare
MOH
$11B
– –
-461,074
Closed -$31.7M –
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2017 Portfolio in Review

As of Q4 2017, Redmile Group held 85 positions worth $2.3B, up 13% from $2.03B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $275M of net new capital in Q4 2017, opening 20 new positions and adding to 27 existing holdings. Its largest new stake was Celgene Corp: 653,000 shares worth $68.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $40.2M trimmed.

  • Redmile Group's largest Q4 2017 buy was Celgene Corp: 653,000 shares worth $68.1M.
  • Redmile Group added most to Syneos Health, Inc. Class A Common Stock in Q4 2017, an estimated $37.3M increase.
  • Redmile Group's biggest Q4 2017 reduction was Seagen Inc. Common Stock, cutting an estimated $40.2M.
  • Redmile Group fully exited Aetna Inc in Q4 2017, selling an estimated $37.2M.
  • Redmile Group's ten largest holdings make up 43% of its $2.3B portfolio in Q4 2017.
  • Redmile Group opened 20 new positions and closed 15 in Q4 2017.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.3B.

Based on Redmile Group's 13F filing for Q4 2017, filed 14 Feb 2018.